
    
      Phase I study to evaluate the excretion of AZD4205 radioactive dose, the metabolic profile,
      pharmacokinetics, safety and tolerability following a single oral administration of
      [14C]-AZD4205 in healthy male volunteers. The purpose of this study is to investigate ADME
      properties of AZD4205 by analyzing blood, urine and feces collected during the study
    
  